Sanofi to launch HIB shot in Japan

Sanofi Pasteur says it's poised to enter the Japanese market with its ActHIB vaccine that targets Haemophilius influenza type b; the shot will be marketed there by Daiichi-Sankyo and will be available beginning next month. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.